Slingshot members are tracking this event:
Idera (IDRA) Agrees to Global License Agreement with Vivelix Pharma to Develop IMO-9200 for Non-Malignant Gastrointestinal (GI) Disorders
Slingshot Insights Explained
Nov 28, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Global License Agreement, Imo-9200, Non-malignant Gastrointestinal, Disorders